# Pioglitazone Hydrochloride in Preventing Radiation-Induced Cognitive Dysfunction in Treating Patients With Brain Tumors

> **NCT01151670** · PHASE1 · COMPLETED · sponsor: **Wake Forest University Health Sciences** · enrollment: 18 (actual)

## Conditions studied

- Brain Neoplasms, Malignant
- Brain Neoplasms, Benign
- Malignant Meningioma
- Glioblastoma Multiforme
- Anaplastic Astrocytoma

## Interventions

- **DRUG:** pioglitazone
- **DRUG:** Pioglitazone

## Key facts

- **NCT ID:** NCT01151670
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2014-08
- **Final completion:** 2014-08
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2018-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01151670

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01151670, "Pioglitazone Hydrochloride in Preventing Radiation-Induced Cognitive Dysfunction in Treating Patients With Brain Tumors". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01151670. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*